Antenatal immunoglobulin for fetal red blood cell alloimmunization

Genotypic Frequency of RHC Antigen in Women of Reproductive Age in Pakistan

“…Moreover, Asian alloantibodies against Rh (E, c) blood groups are the most commonly reported antibodies. 10,11 Therefore, feto-maternal Rh incompatibility still represents the major cause of HDFN.7, 12 ABO distribution analysis in this study demonstrated that 'B' is the most common blood group, followed by O, A and AB, respectively. This finding is in complete agreement with the research conducted by Mahmood et al in the year 2016.…”

“…In Pakistan, maternal alloimmunization during pregnancy is reported as 1.8%, with devastating consequences. 10 Studies have reported that D-antigen is responsible for about 50% of cases of maternal alloimmunization while the remaining are mainly due to incompatibility to c, K, C, e and E antigens and less commonly due to antibodies against MNS and Diego blood group system. Moreover, Asian alloantibodies against Rh (E, c) blood groups are the most commonly reported antibodies.…”

Genotypic Frequency of RHC Antigen in Women of Reproductive Age in Pakistan

“…Moreover, Asian alloantibodies against Rh (E, c) blood groups are the most commonly reported antibodies. 10,11 Therefore, feto-maternal Rh incompatibility still represents the major cause of HDFN.7, 12 ABO distribution analysis in this study demonstrated that 'B' is the most common blood group, followed by O, A and AB, respectively. This finding is in complete agreement with the research conducted by Mahmood et al in the year 2016.…”

“…In Pakistan, maternal alloimmunization during pregnancy is reported as 1.8%, with devastating consequences. 10 Studies have reported that D-antigen is responsible for about 50% of cases of maternal alloimmunization while the remaining are mainly due to incompatibility to c, K, C, e and E antigens and less commonly due to antibodies against MNS and Diego blood group system. Moreover, Asian alloantibodies against Rh (E, c) blood groups are the most commonly reported antibodies.…”

Clinical response to therapeutic plasmapheresis and intravenous immunoglobulin in pregnancies complicated by alloimmunization despite persistently high titers: Report of two cases

“…Several case reports, case series, and case-control studies support the effectiveness and safety of their use, separately or in combination, in patients at risk of early HDFN to delay the need for the first IUBT. 3,4,[6][7][8][9][10][11][12][13][14] A Cochrane review search for randomized clinical trials evaluating the effect of IVIG in pregnancies affected by HDFN failed to identify any trials, 15 and we could not identify any such trials in our literature search. Such a trial is eagerly awaited, given the risk of publication bias and the various regimens described.…”

The contemporary management of haemolytic disease of the fetus and newborn

“…Given these potential side effects, it is important to demonstrate clinical utility. No randomized controlled trials indicate clinical effectiveness [77] but a recently published systematic review of Individual Patient Data (IPD) meta‐analysis has added important information on utility to support its use. This analysis included eight studies [51,69,78–83] comparing 97 cases where IVIg was administered and 97 controls [84].…”

Genotypic Frequency of RHC Antigen in Women of Reproductive Age in Pakistan

“…Moreover, Asian alloantibodies against Rh (E, c) blood groups are the most commonly reported antibodies. 10,11 Therefore, feto-maternal Rh incompatibility still represents the major cause of HDFN.7, 12 ABO distribution analysis in this study demonstrated that 'B' is the most common blood group, followed by O, A and AB, respectively. This finding is in complete agreement with the research conducted by Mahmood et al in the year 2016.…”

“…In Pakistan, maternal alloimmunization during pregnancy is reported as 1.8%, with devastating consequences. 10 Studies have reported that D-antigen is responsible for about 50% of cases of maternal alloimmunization while the remaining are mainly due to incompatibility to c, K, C, e and E antigens and less commonly due to antibodies against MNS and Diego blood group system. Moreover, Asian alloantibodies against Rh (E, c) blood groups are the most commonly reported antibodies.…”

Clinical response to therapeutic plasmapheresis and intravenous immunoglobulin in pregnancies complicated by alloimmunization despite persistently high titers: Report of two cases

“…Several case reports, case series, and case-control studies support the effectiveness and safety of their use, separately or in combination, in patients at risk of early HDFN to delay the need for the first IUBT. 3,4,[6][7][8][9][10][11][12][13][14] A Cochrane review search for randomized clinical trials evaluating the effect of IVIG in pregnancies affected by HDFN failed to identify any trials, 15 and we could not identify any such trials in our literature search. Such a trial is eagerly awaited, given the risk of publication bias and the various regimens described.…”

The contemporary management of haemolytic disease of the fetus and newborn

“…Given these potential side effects, it is important to demonstrate clinical utility. No randomized controlled trials indicate clinical effectiveness [77] but a recently published systematic review of Individual Patient Data (IPD) meta‐analysis has added important information on utility to support its use. This analysis included eight studies [51,69,78–83] comparing 97 cases where IVIg was administered and 97 controls [84].…”

Genotypic Frequency of RHC Antigen in Women of Reproductive Age in Pakistan

“…Moreover, Asian alloantibodies against Rh (E, c) blood groups are the most commonly reported antibodies. 10,11 Therefore, feto-maternal Rh incompatibility still represents the major cause of HDFN.7, 12 ABO distribution analysis in this study demonstrated that 'B' is the most common blood group, followed by O, A and AB, respectively. This finding is in complete agreement with the research conducted by Mahmood et al in the year 2016.…”

“…In Pakistan, maternal alloimmunization during pregnancy is reported as 1.8%, with devastating consequences. 10 Studies have reported that D-antigen is responsible for about 50% of cases of maternal alloimmunization while the remaining are mainly due to incompatibility to c, K, C, e and E antigens and less commonly due to antibodies against MNS and Diego blood group system. Moreover, Asian alloantibodies against Rh (E, c) blood groups are the most commonly reported antibodies.…”

Clinical response to therapeutic plasmapheresis and intravenous immunoglobulin in pregnancies complicated by alloimmunization despite persistently high titers: Report of two cases

“…Several case reports, case series, and case-control studies support the effectiveness and safety of their use, separately or in combination, in patients at risk of early HDFN to delay the need for the first IUBT. 3,4,[6][7][8][9][10][11][12][13][14] A Cochrane review search for randomized clinical trials evaluating the effect of IVIG in pregnancies affected by HDFN failed to identify any trials, 15 and we could not identify any such trials in our literature search. Such a trial is eagerly awaited, given the risk of publication bias and the various regimens described.…”

The contemporary management of haemolytic disease of the fetus and newborn

“…Given these potential side effects, it is important to demonstrate clinical utility. No randomized controlled trials indicate clinical effectiveness [77] but a recently published systematic review of Individual Patient Data (IPD) meta‐analysis has added important information on utility to support its use. This analysis included eight studies [51,69,78–83] comparing 97 cases where IVIg was administered and 97 controls [84].…”